H.C. Wainwright analyst Andres Y. Maldonado maintained a Buy rating on CG Oncology, Inc. (CGON – Research Report) today and set a price target of $75.00.
Andres Y. Maldonado has given his Buy rating due to a combination of factors including the promising results from CG Oncology’s Phase 3 BOND-003 trial for cretostimogene in treating high-risk, BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). The trial data demonstrated a strong complete response rate and a durable response over 24 months, suggesting a best-in-class durability profile that surpasses competitors.
Additionally, cretostimogene’s excellent safety profile, with no severe treatment-related adverse events and high patient adherence, makes it a standout therapy in the NMIBC space. The mechanism of action, which involves tumor-selective viral replication and immune response stimulation, has shown strong translational data, further validating its potential as a leading therapy. These factors, combined with a favorable valuation and price target, underpin Maldonado’s optimistic outlook for CG Oncology’s stock.
In another report released yesterday, LifeSci Capital also maintained a Buy rating on the stock with a $83.00 price target.